IM-1021 is an optimized, ROR1-targeted ADC that incorporates Immunome’s proprietary TOP1 inhibitor, HC74. The Phase 1 trial is an open-label, multicenter dose escalation and expansion study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback